Condition
Romiplostim N01
Total Trials
3
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 2 (1)
Trial Status
Not Yet Recruiting2
Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07214025Not Yet RecruitingPrimary
Safety and Efficacy of Romiplostim in Treatment of Chronic ITP in Children
NCT07162519Not ApplicableNot Yet Recruiting
Romiplostim N01 in the Treatment of Thrombocytopenia Caused by Cytotoxic Drugs in Breast Cancer Patients
NCT07063225Phase 2Recruiting
Romiplostim N01 for Chemotherapy-induced Thrombocytopenia
Showing all 3 trials